Germo Gericke

Germo Gericke's work experience began in 1994 as a Postdoctoral Fellow at Dartmouth Medical School, specializing in Immunology and Oncology. From 1995 to 2001, they worked as an Engagement Manager at McKinsey & Co., Inc. Their career then transitioned to Novartis, where they held various roles including Assistant to the Chairman and CEO, Marketing and Sales Rotation in US-Oncology, Business Unit Head in Transplantation & Immunology, Therapeutic Area Head in Project Management for Dermatology, GI & GU, and Franchise Global Program Head in Oncology Global Development and Medical Affairs. From 2018 to 2020, Germo served as the Global Head of Research & Development and subsequently as the Chief Medical Officer at Advanced Accelerator Applications, a Novartis Company. Currently, they hold the position of Chief Medical Officer at Ariceum Therapeutics since February 2023.

Germo Gericke pursued their Doctor of Medicine (M.D.) degree in Medicine from Humboldt-Universität zu Berlin, which they completed between 1987 and 1993. Additionally, from 1990 to 1993, they attended Heidelberg University, where they obtained a Doctor of Medicine - M.D. degree with a specialization in Immunology/Oncology.